Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

41. Cost-effectiveness of migraine prevention: the case of topiramate in the UK

Cost-effectiveness of migraine prevention: the case of topiramate in the UK Cost-effectiveness of migraine prevention: the case of topiramate in the UK Cost-effectiveness of migraine prevention: the case of topiramate in the UK Brown J S, Papadopoulos G, Neumann P J, Price M, Friedman M, Menzin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study assessed the use of topiramate (TPM, 100 mg/day), a neuromodulatory compound with stabilising properties, as a migraine preventive therapy. This was compared with no preventive therapy. Type of intervention Primary care. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population for the model comprised adults

NHS Economic Evaluation Database.2006

43. Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol depe

Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol depe Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol dependence | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol dependence Article Text Therapeutics Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol dependence Free Mark L Willenbring , MD

Evidence-Based Medicine (Requires free registration)2005

44. Topiramate (Topamax) - Epilepsy

Topiramate (Topamax) - Epilepsy Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Topiramate (Topamax Ò ) (No. 75/03) Janssen Cilag Summary of Recommendation 12 January, 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation (...) is summarised as follows: Advice: following a full submission. Topiramate is accepted for restricted use within NHS Scotland for its extended (monotherapy) indication. It should be initiated only by physicians who have appropriate experience in the treatment of epilepsy. Topiramate should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contraindications

Scottish Medicines Consortium2004

45. Topiramate for migraine prevention: a randomized controlled trial.

Topiramate for migraine prevention: a randomized controlled trial. 14982912 2004 02 25 2004 02 27 2016 10 17 1538-3598 291 8 2004 Feb 25 JAMA JAMA Topiramate for migraine prevention: a randomized controlled trial. 965-73 Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention. To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial. A 26-week, randomized, double-blind, placebo (...) -controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine (International Headache Society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase. After a washout period, patients meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo. Topiramate was titrated by 25 mg/wk for 8 weeks

JAMA2004

46. Topiramate (Topamax) use in treating neuropathic pain

Topiramate (Topamax) use in treating neuropathic pain Topiramate (Topamax) use in treating neuropathic pain Topiramate (Topamax) use in treating neuropathic pain WCB Evidence Based Practice Group Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation WCB Evidence Based Practice Group. Topiramate (Topamax) use in treating neuropathic pain. Richmond, BC: WorkSafe BC 2003 (...) : 4 Authors' objectives This study reviews the use of topiramate (topamax) in treating neuropathic pain. Authors' conclusions To date, there is no high level evidence to support the efficacy of Topiramate in treating neuropathic pain. There is low level anecdotal evidence that suggests this medication may be beneficial in treating diabetic peripheral neuropathy and intercostal neuralgia. It is also worthwhile mentioning that, in general, there is very little information on this medication

Health Technology Assessment (HTA) Database.2003

47. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. 12767733 2003 05 27 2003 06 18 2015 06 16 0140-6736 361 9370 2003 May 17 Lancet (London, England) Lancet Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. 1677-85 Topiramate, a sulphamate fructopyranose derivative, might antagonise alcohol's rewarding effects associated with abuse liability by inhibiting mesocorticolimbic dopamine release via the contemporaneous facilitation (...) of gamma-amino-butyric acid activity and inhibition of glutamate function. We aimed to see whether topiramate was more effective than placebo as a treatment for alcohol dependence. We did a double-blind randomised controlled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals with alcohol dependence. Of these 150 individuals, 75 were assigned to receive topiramate (escalating dose of 25-300 mg per day) and 75 had placebo as an adjunct to weekly standardised

Lancet2003

48. Topiramate add-on for drug-resistant partial epilepsy.

Topiramate add-on for drug-resistant partial epilepsy. BACKGROUND: The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 30 per cent develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug resistant partial epilepsy. OBJECTIVES: To evaluate (...) the effects of topiramate when used as an add-on treatment for drug-resistant partial epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group's specialized register (28 March 2002); the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2002). In addition, we contacted Johnson and Johnson (makers of topiramate) and experts in the field to seek any ongoing or unpublished studies. SELECTION CRITERIA: Randomized placebo controlled add-on trials of topiramate recruiting people with drug

Cochrane2002

49. Topiramate: a review of its use in childhood epilepsy

Topiramate: a review of its use in childhood epilepsy Topiramate: a review of its use in childhood epilepsy Topiramate: a review of its use in childhood epilepsy Ormrod D, McClellan K Authors' objectives To review the use of topiramate in childhood epilepsy. Searching MEDLINE, EMBASE and AdisBase were searched to March 2001. The key terms were stated. The reference lists of published reports were examined and the pharmaceutical company who had developed the drug was contacted for further (...) published and unpublished data. Study selection Study designs of evaluations included in the review The inclusion criteria were not explicitly defined in terms of the study design. Double-blind randomised controlled trials (RCTs), with and without open extensions, and non-comparative studies (retrospective and prospective post-marketing studies) were used to assess treatment efficacy. Meta-analyses were also included. Specific interventions included in the review Studies of topiramate were eligible

DARE.2001

50. Topiramate for drug-resistant partial epilepsy.

Topiramate for drug-resistant partial epilepsy. BACKGROUND: The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the efficacy (...) and tolerability of topiramate when used as an add-on treatment in patients with drug resistant partial epilepsy. SEARCH STRATEGY: (a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field. SELECTION CRITERIA: Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected trials

Cochrane2000